Literature DB >> 21270370

Staggered meal consumption facilitates appetite control without affecting postprandial energy intake.

Sofie G Lemmens1, Eveline A Martens, Jurriaan M Born, Mieke J Martens, Margriet S Westerterp-Plantenga.   

Abstract

Meal pattern may influence hormone and appetite dynamics and food intake. The objective of the study was to determine the effects of staggered compared with nonstaggered meal consumption on hormone and appetite dynamics, food reward (i.e. "liking," "wanting"), and subsequent energy intake. The study was conducted in a randomized cross-over design. Participants (n = 38, age = 24 ± 6 y, BMI = 25.0 ± 3.1 kg/m(2)) came to the university twice for consumption of a 4-course lunch (40% of the daily energy requirements) in 0.5 h (nonstaggered) or in 2 h with 3 within-meal pauses (staggered) followed by ad libitum food intake. Throughout the test sessions, glucagon-like peptide (GLP)-1, peptide tyrosine-tyrosine (PYY(3-36)), ghrelin, appetite, and food reward were measured. In the staggered compared with nonstaggered meal condition, peak values of GLP-1, PYY(3-36), and satiety were lower and time to peak values were higher (P < 0.02); the nadir value of hunger was higher, and time to nadir values of ghrelin and hunger were higher (P < 0.0001). Prior to ad libitum food intake, GLP-1 concentrations and satiety ratings were greater, ghrelin concentrations and hunger ratings were smaller, and food "wanting" was less in the staggered compared with nonstaggered meal condition (P < 0.05). However, this did not affect ad libitum energy intake (1.7 ± 0.3 vs. 1.9 ± 0.2 MJ). In conclusion, staggered compared with nonstaggered meal consumption induces less pronounced hormone and appetite dynamics. Moreover, it results in higher final GLP-1 concentrations and satiety ratings, lower ghrelin concentrations and hunger ratings, and lower food "wanting" prior to ad libitum food intake. However, this was not translated into lower energy intake.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21270370     DOI: 10.3945/jn.110.133264

Source DB:  PubMed          Journal:  J Nutr        ISSN: 0022-3166            Impact factor:   4.798


  6 in total

Review 1.  Examining weight suppression as a transdiagnostic factor influencing illness trajectory in bulimic eating disorders.

Authors:  Pamela K Keel; Lindsay P Bodell; K Jean Forney; Jonathan Appelbaum; Diana Williams
Journal:  Physiol Behav       Date:  2019-05-30

2.  Obesity susceptibility loci and dietary intake in the Look AHEAD Trial.

Authors:  Jeanne M McCaffery; George D Papandonatos; Inga Peter; Gordon S Huggins; Hollie A Raynor; Linda M Delahanty; Lawrence J Cheskin; Ashok Balasubramanyam; Lynne E Wagenknecht; Rena R Wing
Journal:  Am J Clin Nutr       Date:  2012-04-18       Impact factor: 7.045

3.  Plasma acyl-ghrelin increases after meal initiation: a new insight.

Authors:  K Seyssel; X Allirot; J-A Nazare; H Roth; E Blond; A Charrié; A Mialon; J Drai; M Laville; E Disse
Journal:  Eur J Clin Nutr       Date:  2015-10-28       Impact factor: 4.016

4.  Correlations of circulating peptide YY and ghrelin with body weight, rate of weight gain, and time required to achieve the recommended daily intake in preterm infants.

Authors:  XiaFang Chen; XueLiang Du; JianXing Zhu; LiJuan Xie; YongJun Zhang; ZhenJuan He
Journal:  Braz J Med Biol Res       Date:  2012-04-26       Impact factor: 2.590

5.  Effect of reducing portion size at a compulsory meal on later energy intake, gut hormones, and appetite in overweight adults.

Authors:  Hannah B Lewis; Amy L Ahern; Ivonne Solis-Trapala; Celia G Walker; Frank Reimann; Fiona M Gribble; Susan A Jebb
Journal:  Obesity (Silver Spring)       Date:  2015-06-05       Impact factor: 5.002

Review 6.  Portion, package or tableware size for changing selection and consumption of food, alcohol and tobacco.

Authors:  Gareth J Hollands; Ian Shemilt; Theresa M Marteau; Susan A Jebb; Hannah B Lewis; Yinghui Wei; Julian P T Higgins; David Ogilvie
Journal:  Cochrane Database Syst Rev       Date:  2015-09-14
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.